Evidence map›Paper›PMID 32057315›Full record

ArticleThe Lancet. Public health2020

Projected time to elimination of cervical cancer in the USA: a comparative modelling study.

Emily A Burger, Megan A Smith, James Killen, Stephen Sy, Kate T Simms, Karen Canfell, Jane J Kim

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Adapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Unveiling the functions of five recently characterized lncRNAs in cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Emily A BurgerHarvard T H Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway. Electronic address: eburger@hsph.harvard.edu.
Megan A SmithCancer Research Division, Cancer Council NSW, Sydney NSW, Australia; School of Public Health, University of Sydney, Sydney, NSW, Australia.
James KillenCancer Research Division, Cancer Council NSW, Sydney NSW, Australia.
Stephen SyHarvard T H Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA.
Kate T SimmsCancer Research Division, Cancer Council NSW, Sydney NSW, Australia; School of Public Health, University of Sydney, Sydney, NSW, Australia.
Karen CanfellCancer Research Division, Cancer Council NSW, Sydney NSW, Australia; School of Public Health, University of Sydney, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
Jane J KimHarvard T H Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA.
Cancer Council NSW · AUUniversity of Oslo · NO

Funding

Comparative Modeling to Inform Cervical Cancer Control PoliciesU01CA199334 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNABAS, RUANNE VANESSA, CANFELL, KAREN · 2015 to 2019
$6.4M
NCI NIH HHS U01 CA199334
6 · The paper itself

Abstract

backgroundIn May, 2018, the Director-General of WHO issued a global call to eliminate cervical cancer as a public health problem, which will involve ambitious screening and vaccination coverage targets. We aimed to assess the potential for, and timing of, cervical cancer elimination in the USA and whether this could be expedited by adopting ambitious coverage targets, using two cervical cancer simulation models.

methodsIn this modelling study, we used two independently-developed cervical cancer microsimulation models-Harvard and Policy1-Cervix-to estimate changes in the incidence of human papillomavirus (HPV)-induced cervical cancer over time in the USA, including herd effects from vaccination. We compared nine alternative scenarios for prophylactic HPV vaccination and cervical screening scale-up with a status quo scenario that involved no additional interventions in the context of a threshold for cervical cancer elimination of four or fewer cases per 100 000 women-years. We also estimated the number of cervical cancer cases that could be averted between 2019 and 2100 associated with the adoption of ambitious goals for cervical cancer screening and vaccination coverage, and other potential strategies.

findingsUnder status quo assumptions, the Havard and Policy1-Cervix models projected that cervical cancer incidence would decrease to less than four or fewer new cases per 100 000 women-years by the 2038 and 2046, respectively. Scaling up screening coverage to 90% in 2020, was the most effective intervention to expedite time to elimination (10-13-year reduction), averting a mean of 1400-2088 additional cases annually between 2019 and 2100. Increasing HPV vaccination coverage to 90% or vaccinating adults aged 26-45 years had relatively little effect on cervical cancer incidence. Sensitivity analysis using different population structures resulted in differences in time to elimination (range -10 years to +27 years) compared with status quo predictions.

interpretationThe USA is on track to eliminate cervical cancer as a public health problem in the next two to three decades. Time to elimination could be expedited by 10-13 years by achieving higher screening coverage. Targeting of underscreened and under-vaccinated women remains key to achieving cervical cancer elimination for all women.

fundingUS National Cancer Institute.

Indexed as

Disease EradicationAdultEarly Detection of CancerFemaleForecastingHumansIncidenceMiddle AgedModels, StatisticalPapillomavirus VaccinesUnited StatesUterine Cervical NeoplasmsPapillomavirus Vaccines

Identifiers

PMID32057315
PMCPMC8715100
OpenAlexW3004459454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.